ENTPD2 and neoplasm: The combination of ENTPD2 inhibitors and immune checkpoint inhibitors significantly increased the infiltration of T cells into the tumor and prolonged survival of tumor-bearing mice, when compared to using immune checkpoint inhibitors alone [130].